No profile data available.
Eli Lilly and Company (LLY) is a healthcare company in the blood sugar management drugs industry, based in Indianapolis, United States, with about 50,000 full-time employees.
It reported revenue of $65.18 billion for fiscal year 2025, up 44.7% from fiscal year 2024, and net income of $20.64 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $22.97 billion, up 47.7% from a year before. United States was its largest region in fiscal year 2025, with 67% of revenue. Its market capitalization was $1.05 trillion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Eli Lilly and reported $65.18 billion in revenue for fiscal year 2025, up 44.7% from $45.04 billion in fiscal year 2024. In Q2 2026 revenue was $22.97 billion.
United States: 67% of revenue by region in fiscal year 2025, followed by Europe (18%).
$1.05 trillion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood sugar management drugs) include Novo Nordisk A/S (NVO), Oramed Pharmaceuticals Inc. (ORMP), Biomea Fusion, Inc. (BMEA), Vicapsys Life Sciences, Inc. (VICP).